While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated
Singapore has vaccinated almost half its 5.7 million population with at least one dose of the vaccines from Pfizer-BioNTech and Moderna. Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with Sinovac's 51%.
Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.
Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.
The world's second-most populous country this month recorded its highest monthly COVID-19 death toll since the pandemic began last year, accounting for just over a third of the overall total.
India reported 211,298 new infections on Thursday, the world's highest daily rise, but nearly half the daily infections it recorded earlier this month.
Dr. Sudharshani Fernandopulle, the minister overseeing the fight against the epidemic, said in a statement the government would order 5 million doses of the Pfizer vaccine.
Sri Lanka is the first country in South Asia to approve the Pfizer vaccine. It has also approved Russia's Sputnik and China's Sinopharm vaccines for emergency use.
Over the weekend, the health ministry announced that 30% fewer vaccines had been received between January and April than expected. Queiroga said the Covax facility, an international cooperation to assist countries secure vaccines, had moved up the expected delivery of 2 million doses to May.
It added that it had secured a total 192 million doses of vaccines, including those from Moderna Inc, AstraZeneca PLC, Johnson & Johnson's and Novavax.
"The government has acquired COVID-19 vaccines large enough to vaccinate approximately 100 million people...(which) is double the entire population of South Korea," Health Minister Kwon Deok-cheol told a briefing.
Ursula von der Leyen said the earlier deliveries, which will start this month, will take total supplies to the EU from Pfizer to 250 million doses in the second quarter of this year.
She also confirmed the Commission was in talks with the two companies for a new contract for 1.8 billion doses to be delivered in 2022 and 2023, confirming a Reuters report last week.
"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
The deal is another fillip for the country worst hit by COVID-19 infections in Africa as it adds to the 31 million single-shot doses from Johnson & Johnson which the government approved on Thursday.
The country has also been allocated 12 million shots under the World Health Organization's COVAX scheme and is likely to get doses for 10 million people from the African Union's AVATT initiative.
"We were surprised, and very pleased," Moss told reporters at a briefing about the findings. "But, of course, this does go with the excellent clinical protection that we're seeing with the vaccine - so it does correlate."
Pfizer and its co-developer BioNTech said earlier on Thursday that updated clinical trial data showed their vaccine is around 91% effective at preventing COVID-19 cases.
The doses to vaccinate two million people will be supplied in addition to the planned deliveries, to ease border movement and to tackle virus hotspots, the Commission said.
"To tackle aggressive variants of the virus and to improve the situation in hotspots, quick and decisive action is necessary," the president of the Commission, Ursula von der Leyen, said.
Speaking in Brasilia, Guedes said President Jair Bolsonaro had spoken with the global head of Pfizer and was scheduled to speak with the head of Janssen, the pharmaceutical subsidiary of Johnson & Johnson.
The government last week said it intended to buy 100 million doses from Pfizer and 38 million from Janssen through the end of December.
The Pfizer/BioNTech shot is the first vaccine against the novel coronavirus to receive full approval in Brazil, Anvisa said. Other vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use so far.
The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling.
"Overall, we're seeing a really strong effect to reducing any infection, asymptomatic and symptomatic," PHE's strategic response director Susan Hopkins told a media briefing.
"Hospitalisation and deaths rates are falling in all age groups, but the oldest age groups are seeing the fastest decline since the peak in mid-January," a PHE statement said.